|
This expert interview from the 2010 Oncology Annual Meeting focuses on the following data release: #LBA1: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study |
|
| Discussant: |
Michael Birrer, MD, PhD—Massachusetts General Hospital, Boston, Massachusetts, United States
|
| Interviewed by: |
Bradley Monk, MD—University of California Irvine, Orange, California, United States
|
|
|
